The bidirectional relationship between fatty liver disease and COVID-19

Abstract

COVID-19 and nonalcoholic fatty liver disease (NAFLD) have emerged as global pandemics affecting millions of people worldwide over the past three years. NAFLD is particularly prevalent in individuals with metabolic comorbidities, such as diabetes and obesity, which have been strongly linked to a severe course of Sars-CoV-2 infection. Recently, due to the close association between metabolic abnormalities and NAFLD, the disease has been redefined as metabolic dysfunction-associated fatty liver disease (MAFLD). This review offers an overview of the biological and cellular mechanisms by which COVID-19 can cause liver damage, with a specific focus on the influence of fatty liver in these mechanisms. Additionally, it explores how fatty liver can exacerbate a COVID-19 infection and, conversely, if the presence of COVID-19 may accelerate the development and progression of fatty liver. Finally, the review examines the existing evidence suggesting that NAFLD or MAFLD independently contributes to a heightened severity of COVID-19, while also considering other factors such as age and metabolic comorbidities that may play a role in the disease’s progression.

Keywords

MAFLD / NAFLD / fatty liver / COVID-19 / SARS-CoV-2

References

[1] Wiersinga WJ,Cheng AC,Prescott HC.Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review.JAMA2020;324:782-93

[2] Díaz LA,Fuentes-López E,Medina RA.Symptom profiles and risk factors for hospitalization in patients with SARS-CoV-2 and COVID-19: a large cohort from South America.Gastroenterology2020;159:1148-50 PMCID:PMC7207141

[3] Ejaz H,Zafar A.COVID-19 and comorbidities: deleterious impact on infected patients.J Infect Public Health2020;13:1833-9 PMCID:PMC7402107

[4] Zhou Y,Lv W.Obesity and diabetes as high-risk factors for severe coronavirus disease 2019 (Covid-19).Diabetes Metab Res Rev2021;37:e3377 PMCID:PMC7361201

[5] Steenblock C,Ludwig B.COVID-19 and metabolic disease: mechanisms and clinical management.Lancet Diabetes Endocrinol2021;9:786-98 PMCID:PMC8489878

[6] Younossi ZM,de Avila L.The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis.J Hepatol2019;71:793-801

[7] Mundi MS,Patel J,Abu Dayyeh BK.Evolution of NAFLD and its management.Nutr Clin Pract2020;35:72-84

[8] European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of nonalcoholic fatty liver disease.J Hepatol2016;64:1388-402

[9] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.J Hepatol2020;73:202-9

[10] Eslam M,George J.MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease.Gastroenterology2020;158:1999-2014.e1

[11] Younossi ZM,Sanyal AJ.From NAFLD to MAFLD: implications of a premature change in terminology.Hepatology2021;73:1194-8

[12] Mohamadian M,Shoghli A,Parsamanesh N.COVID-19: virology, biology and novel laboratory diagnosis.J Gene Med2021;23:e3303 PMCID:PMC7883242

[13] Nardo AD,Bakail M,Lax SF.Pathophysiological mechanisms of liver injury in COVID-19.Liver Int2021;41:20-32 PMCID:PMC7753756

[14] Khailany RA,Ozaslan M.Genomic characterization of a novel SARS-CoV-2.Gene Rep2020;19:100682 PMCID:PMC7161481

[15] Fehr AR.Coronaviruses: an overview of their replication and pathogenesis.Methods Mol Biol2015;1282:1-23 PMCID:PMC4369385

[16] V'kovski P,Steiner S,Thiel V.Coronavirus biology and replication: implications for SARS-CoV-2.Nat Rev Microbiol2021;19:155-70 PMCID:PMC7592455

[17] Voto C,Brenner C.Overview of the pathogenesis and treatment of SARS-CoV-2 for clinicians: a comprehensive literature review.Cureus2020;12:e10357 PMCID:PMC7549853

[18] Tan YJ,Hong W.Understanding the accessory viral proteins unique to the severe acute respiratory syndrome (SARS) coronavirus.Antiviral Res2006;72:78-88 PMCID:PMC7114237

[19] Datta PK,Fischer T,Qin X.SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy.Theranostics2020;10:7448-64 PMCID:PMC7330865

[20] Tikellis C.Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease.Int J Pept Res Ther2012;2012:1-8 PMCID:PMC3321295

[21] Pirola CJ.SARS-CoV-2 virus and liver expression of host receptors: Putative mechanisms of liver involvement in COVID-19.Liver Int2020;40:2038-40 PMCID:PMC7267350

[22] Yang L,Nilsson-Payant BE.A human pluripotent stem cell-based platform to study sars-cov-2 tropism and model virus infection in human cells and organoids.Cell Stem Cell2020;27:125-136.e7 PMCID:PMC7303620

[23] Ou X,Lei X.Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV.Nat Commun2020;11:1620 PMCID:PMC7100515

[24] Crudele A,Ingegneri M.Hydroxytyrosol recovers SARS-CoV-2-PLpro-Dependent impairment of interferon related genes in polarized human airway, intestinal and liver epithelial cells.Antioxidants2022;11:1466 PMCID:PMC9404978

[25] Li J.Characteristics and mechanism of liver injury in 2019 coronavirus disease.J Clin Transl Hepatol2020;8:13-7 PMCID:PMC7132021

[26] Zhang C,Wang FS.Liver injury in COVID-19: management and challenges.Lancet Gastroenterol2020;5:428-30 PMCID:PMC7129165

[27] Vujčić I.Outcomes of COVID-19 among patients with liver disease.World J Gastroenterol2023;29:815-24 PMCID:PMC9932431

[28] Huang Q,Shi CC.Expression of angiotensin-converting enzyme 2 in CCL4-induced rat liver fibrosis.Int J Mol Med2009;23

[29] Fondevila MF,Rodríguez A.Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points.J Hepatol2021;74:469-71 PMCID:PMC7574841

[30] Singh MK,Chandra A,Ramachandran S.A meta-analysis of comorbidities in COVID-19: which diseases increase the susceptibility of SARS-CoV-2 infection?.Comput Biol Med2021;130:104219 PMCID:PMC7836641

[31] Sharifi Y,Mohammadi-Vajari E.Association between cardiometabolic risk factors and COVID-19 susceptibility, severity and mortality: a review.J Diabetes Metab Disord2021;20:1743-65 PMCID:PMC8233632

[32] Rubino F,Zimmet P.New-onset diabetes in Covid-19.N Engl J Med2020;383:789-90 PMCID:PMC7304415

[33] Govender N,Moodley J.Insulin resistance in COVID-19 and diabetes.Prim Care Diabetes2021;15:629-34 PMCID:PMC8031259

[34] Mozafari N,Mehdi-Alamdarlou S,Azadi A.Inflammation: a bridge between diabetes and COVID-19, and possible management with sitagliptin.Med Hypotheses2020;143:110111 PMCID:PMC7361050

[35] Li X,Peng Y,Lu S.Molecular immune pathogenesis and diagnosis of COVID-19.J Pharm Anal2020;10:102-8 PMCID:PMC7104082

[36] Dorrington MG.NF-κB signaling in macrophages: dynamics, crosstalk, and signal integration.Front Immunol2019;10:705 PMCID:PMC6465568

[37] Ge J,Liang C.Advanced glycosylation end products might promote atherosclerosis through inducing the immune maturation of dendritic cells.Arterioscler Thromb Vasc Biol2005;25:2157-63

[38] Alba-Loureiro TC,Martins JO.Neutrophil function and metabolism in individuals with diabetes mellitus.Braz J Med Biol Res2007;40:1037-44

[39] Korakas E,Kousathana F.Obesity and COVID-19: immune and metabolic derangement as a possible link to adverse clinical outcomes.Am J Physiol Endocrinol Metab2020;319:E105-9 PMCID:PMC7322508

[40] Kulcsar KA,Beck SE.Comorbid diabetes results in immune dysregulation and enhanced disease severity following MERS-CoV infection.JCI Insight2019;4:131774 PMCID:PMC6824443

[41] Tian W,Yao J.Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis.J Med Virol2020;92:1875-83 PMCID:PMC7280666

[42] Zhang JJ,Tan G.Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients.Allergy2021;76:533-50 PMCID:PMC7404752

[43] Rapp JL,Tuminello S.Male sex, severe obesity, older age, and chronic kidney disease are associated with COVID-19 severity and mortality in New York city.Chest2021;159:112-5 PMCID:PMC7455228

[44] Ebinger JE,Ji H.Pre-existing traits associated with Covid-19 illness severity.PLoS One2020;15:e0236240 PMCID:PMC7377468

[45] Gao F,Wang XB.Obesity is a risk factor for greater COVID-19 severity.Diabetes Care2020;43:e72-4

[46] Clift AK,Keogh RH.Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study.BMJ2020;371:m3731 PMCID:PMC7574532

[47] Dennis JM,Sonabend R.Type 2 diabetes and COVID-19-related mortality in the critical care setting: a national cohort study in England, March-July 2020.Diabetes Care2021;44:50-7 PMCID:PMC7783930

[48] Williamson EJ,Bhaskaran K.Factors associated with COVID-19-related death using OpenSAFELY.Nature2020;584:430-6 PMCID:PMC7611074

[49] Li X,Yu M.Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan.J Allergy Clin Immunol2020;146:110-8 PMCID:PMC7152876

[50] Richardson S,Narasimhan M.the Northwell COVID-19 Research ConsortiumPresenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area.JAMA2020;323:2052-9 PMCID:PMC7177629

[51] Henry L,Younossi ZM.Review article: the epidemiologic burden of nonalcoholic fatty liver disease across the world.Aliment Pharmacol Ther2022;56:942-56

[52] Díaz LA,Cannistra M.High prevalence of hepatic steatosis and vascular thrombosis in COVID-19: a systematic review and meta-analysis of autopsy data.World J Gastroenterol2020;26:7693-706 PMCID:PMC7789052

[53] Wang G,Wu C.Association between nonalcoholic fatty liver disease with the susceptibility and outcome of COVID-19: a retrospective study.J Cell Mol Med2021;25:11212-20 PMCID:PMC8650045

[54] Chen N,Dong X.Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.Lancet2020;395:507-13 PMCID:PMC7135076

[55] Ji D,Xu J.Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study.J Hepatol2020;73:451-3 PMCID:PMC7141624

[56] Cai Q,Yu H.COVID-19: Abnormal liver function tests.J Hepatol2020;73:566-74 PMCID:PMC7194951

[57] Huang R,Wang J.Clinical features of patients with COVID-19 with nonalcoholic fatty liver disease.Hepatol Commun2020;4:1758-68 PMCID:PMC7436597

[58] Portincasa P,Smyk W,Di Ciaula A.COVID-19 and nonalcoholic fatty liver disease: two intersecting pandemics.Eur J Clin Invest2020;50:e13338 PMCID:PMC7361203

[59] Martinez MA.Impact of COVID-19 in liver disease progression.Hepatol Commun2021;5:1138-50 PMCID:PMC8239862

[60] Nagarajan R,Rajaa S.COVID-19 severity and mortality among chronic liver disease patients: a systematic review and meta-analysis.Prev Chronic Dis2022;19:E53 PMCID:PMC9480842

[61] Gao F,Wang XB.Metabolic associated fatty liver disease increases coronavirus disease 2019 disease severity in nondiabetic patients.J Gastroenterol Hepatol2021;36:204-7 PMCID:PMC7280625

[62] Younossi ZM,Lam B.Independent predictors of mortality among patients with NAFLD hospitalized with COVID-19 infection.Hepatol Commun2022;6:3062-72 PMCID:PMC8426701

[63] Targher G,Byrne CD.Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores.Gut2020;69:1545-7

[64] Yao R,Wang J.Risk of severe illness of COVID-19 patients with NAFLD and increased NAFLD fibrosis scores.J Clin Lab Anal2021;35:e23880 PMCID:PMC8373321

[65] Vázquez-Medina MU,Galeana-Pavón A.Interaction of metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease with advanced fibrosis in the death and intubation of patients hospitalized with coronavirus disease 2019.Hepatol Commun2022;6:2000-10 PMCID:PMC9110946

[66] Marjot T,Boettler T.Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: an updated EASL position paper.J Hepatol2022;77:1161-97 PMCID:PMC9296253

[67] Tao Z,Cheng B,Gao Y.Risk of severe COVID-19 increased by metabolic dysfunction-associated fatty liver disease: a meta-analysis.J Clin Gastroenterol2021;55:830-5 PMCID:PMC8500209

[68] Pan L,Xie X,Guo D.Metabolic associated fatty liver disease increases the severity of COVID-19: a meta-analysis.Dig Liver Dis2021;53:153-7 PMCID:PMC7498251

[69] Singh A,Antony B.nonalcoholic fatty liver disease and clinical outcomes in patients with COVID-19: a comprehensive systematic review and meta-analysis.Diabetes Metab Syndr2021;15:813-22 PMCID:PMC8011308

[70] Sachdeva S,Kopel J,Desai R.NAFLD and COVID-19: a pooled analysis.SN Compr Clin Med2020;2:2726-9 PMCID:PMC7646222

[71] Hegyi PJ,Ocskay K.Metabolic associated fatty liver disease is associated with an increased risk of severe COVID-19: a systematic review with meta-analysis.Front Med2021;8:626425 PMCID:PMC7994270

[72] Wang Y,Duan G.NAFLD was independently associated with severe COVID-19 among younger patients rather than older patients: a meta-analysis.J Hepatol2023;78:e136-9 PMCID:PMC9597581

[73] Forlano R,Mukherjee SK.In-hospital mortality is associated with inflammatory response in NAFLD patients admitted for COVID-19.PLoS One2020;15:e0240400 PMCID:PMC7544083

[74] Mushtaq K,Iqbal F.NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - the debate continues.J Hepatol2021;74:482-4 PMCID:PMC7836329

[75] Li J,Zhu H.Mendelian randomization analysis reveals no causal relationship between nonalcoholic fatty liver disease and severe COVID-19.Clin Gastroenterol H2022;20:1553-1560.e78 PMCID:PMC8812093

[76] Wang Y,Liu H.SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19.J Hepatol2020;73:807-16 PMCID:PMC7211738

[77] Lebeaupin C,Hazari Y,Chevet E.Endoplasmic reticulum stress signalling and the pathogenesis of nonalcoholic fatty liver disease.J Hepatol2018;69:927-47

[78] Chan CP,Chin KT,Zheng B.Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein.J Virol2006;80:9279-87 PMCID:PMC1563899

[79] Banerjee A,Reiter RJ.Crosstalk between endoplasmic reticulum stress and anti-viral activities: a novel therapeutic target for COVID-19.Life Sci2020;255:117842 PMCID:PMC7245231

[80] Kindrachuk J,Hart BJ.Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis.Antimicrob Agents Ch2015;59:1088-99 PMCID:PMC4335870

[81] He M,Yang M,Li T.Mesenchymal stem cells-derived IL-6 activates AMPK/mTOR signaling to inhibit the proliferation of reactive astrocytes induced by hypoxic-ischemic brain damage.Exp Neurol2019;311:15-32

[82] Serebrovska ZO,Serebrovska TV,Xi L.Hypoxia, HIF-1α, and COVID-19: from pathogenic factors to potential therapeutic targets.Acta Pharmacol Sin2020;41:1539-46 PMCID:PMC7588589

[83] Gonzalez FJ,Jiang C.The role of hypoxia-inducible factors in metabolic diseases.Nat Rev Endocrinol2018;15:21-32 PMCID:PMC6624429

[84] Chen J,Fu H.Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway.Am J Physiol-Endoc M2019;317:E710-22

[85] Arrese M,Kalergis AM.Innate immunity and inflammation in NAFLD/NASH.Dig Dis Sci2016;61:1294-303 PMCID:PMC4948286

[86] Schmidt-Arras D.IL-6 pathway in the liver: from physiopathology to therapy.J Hepatol2016;64:1403-15

[87] Miele L,Cesario A.COVID-19, adaptative immune response and metabolic-associated liver disease.Liver Int2021;41:2560-77 PMCID:PMC8661993

[88] Fricker ZP,Massaro JM.Liver fat is associated with markers of inflammation and oxidative stress in analysis of data from the framingham heart study.Clin Gastroenterol Hepatol2019;17:1157-1164.e4 PMCID:PMC6475462

[89] Sharma P,Anikhindi S.Effect of COVID-19 on pre-existing liver disease: what hepatologist should know?.J Clin Exp Hepatol2021;11:484-93 PMCID:PMC7774459

[90] Prins GH.Potential implications of COVID-19 in nonalcoholic fatty liver disease.Liver Int2020;40:2568 PMCID:PMC7264616

[91] Kilian C,Allebeck P.Alcohol consumption during the COVID-19 pandemic in Europe: a large-scale cross-sectional study in 21 countries.Addiction2021;116:3369-80